GO:0050436 microfibril binding: Mechanism, Genes and Research

Microfibrils are small fibrillar structures found in the extracellular matrix of many tissues, and the molecular function of binding to these structures is captured by the Gene Ontology term GO:0050436 (microfibril binding). This term describes the selective interaction of proteins with microfibrils, a function that is central to the assembly and remodelling of elastic fibres in connective tissues such as skin, lung, blood vessels and tendon [1,2]. The best-characterized microfibril-binding proteins are the fibrillins (FBN1, FBN2, FBN3), which form the structural core of microfibrils and serve as docking sites for numerous associated proteins [1,5]. Understanding microfibril binding is therefore fundamental to extracellular matrix biology and to the pathogenesis of inherited connective-tissue disorders [1,6]. At the molecular level, microfibril binding is mediated by specific domains within fibrillins and their partners, including latent TGF-beta-binding proteins (LTBPs) and microfibril-associated glycoprotein-1 (MFAP1) [4,8]. These interactions are not merely structural; they regulate the sequestration and release of latent growth factors, thereby influencing cell signalling and tissue homeostasis [4,6]. The functional importance of microfibril binding is underscored by pathogenic mutations in fibrillin-1 that alter microfibril structure and disrupt a key regulatory latent TGF-beta-binding site. For researchers, GO:0050436 provides a precise annotation for proteins that physically associate with microfibrils, enabling systematic analysis of extracellular matrix assembly, growth factor regulation and disease mechanisms [1,3]. This article reviews the definition, mechanism, key genes, disease links and experimental approaches relevant to microfibril binding, with a focus on CRISPR-based models for functional studies.

GO:0050436 (microfibril binding) is a molecular function term defined as the binding to a microfibril, any small fibril occurring in biological material. In practice, this means the ability of a protein to selectively and non-covalently interact with microfibrillar structures, which are typically composed of fibrillin polymers and associated proteins in the extracellular matrix [1,5].

Microfibril binding is important because microfibrils are essential structural components of elastic fibres, and the proteins that bind to them control both matrix architecture and the availability of latent growth factors such as TGF-beta [1,4]. Disruption of microfibril binding due to mutations in fibrillin-1 causes Marfan syndrome and related disorders, highlighting its direct clinical relevance. Moreover, microfibril-binding proteins are emerging as modulators of tissue development, repair and disease progression, making GO:0050436 a key annotation for extracellular matrix research [1,3].

The following genes encode proteins that bind to or constitute microfibrils, as supported by published literature.

Microfibril binding is regulated at multiple levels, including the expression and secretion of fibrillins and LTBPs, proteolytic processing of microfibril-associated proteins, and the availability of latent TGF-beta complexes [1,4]. LTBP4, for instance, undergoes proteolytic cleavage that affects its interaction with microfibrils and its ability to regulate TGF-beta. Pathogenic mutations in fibrillin-1 can alter the conformation of a key regulatory latent TGF-beta-binding site, thereby affecting microfibril binding and downstream signalling. Additionally, extracellular matrix remodelling enzymes such as lysyl oxidase influence the stability of microfibril-associated elastic fibres.

Mutations in FBN1 that impair microfibril binding and assembly cause Marfan syndrome, characterized by cardiovascular, skeletal and ocular abnormalities. These mutations can disrupt a key regulatory latent TGF-beta-binding site, leading to altered TGF-beta signalling and tissue fragility.

LTBP4 is a microfibril-binding protein that regulates TGF-beta bioavailability, and its dysfunction has been linked to conditions affecting elastic tissues, including cardiovascular and pulmonary diseases. Research into LTBP4 in health and disease highlights the importance of microfibril binding in tissue homeostasis.

Progressive loss of elastic fibres contributes to aging and diseases such as emphysema and arterial stiffening, processes in which microfibril-binding proteins play a central role [1,3]. Understanding microfibril binding may inform therapeutic strategies to preserve or restore elastic fibre integrity.

Microfibril binding can be visualized using immunofluorescence with antibodies against fibrillin-1 or MFAP1, and ultrastructural details are resolved by electron microscopy [1,2]. These methods reveal the distribution and integrity of microfibrils in tissues and cultured cells.

Co-immunoprecipitation, pull-down assays and surface plasmon resonance are used to measure direct binding between microfibril components such as fibrillin-2 and MFAP1. These techniques help define binding domains and affinities.

CRISPR knockout, point-mutation and knock-in models allow precise testing of the functional consequences of altered microfibril binding in relevant cell types [6,8]. These approaches can be combined with biochemical and imaging readouts.

RNA sequencing and mass spectrometry-based proteomics can identify changes in extracellular matrix gene expression and protein interactions resulting from mutations in microfibril-binding proteins [4,7]. Such analyses provide systems-level insights into microfibril biology.

Researchers studying microfibril binding-related genes often need to determine whether a candidate gene is causally involved in microfibril assembly, growth factor regulation or disease pathogenesis. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such functional studies.

GO:0050436 (microfibril binding) defines a critical molecular function in extracellular matrix biology, centered on the interaction of proteins such as fibrillins, LTBPs and MFAP1 with microfibrils [1,4,8]. This function is essential for elastic fibre assembly and the regulation of latent TGF-beta signalling, and its disruption underlies inherited connective-tissue disorders like Marfan syndrome. Continued research using CRISPR-based models will further elucidate the mechanistic details and therapeutic potential of targeting microfibril binding [6,8].